Journal Mobile Options
Table of Contents
Vol. 3, No. 6, 2006
Issue release date: January 2007
Section title: Original Paper
Neurodegenerative Dis 2006;3:327–333
(DOI:10.1159/000097301)

Association of Tau Haplotype-Tagging Polymorphisms with Parkinson’s Disease in Diverse Ethnic Parkinson’s Disease Cohorts

Fung H.C.b-d · Xiromerisiou G.a, e · Gibbs J.R.a · Wu Y.R.d · Eerola J.f · Gourbali V.e · Hellström O.f · Chen C.M.d · Duckworth J.a · Papadimitriou A.e · Tienari P.J.g · Hadjigeorgiou G.M.e · Hardy J.b · Singleton A.B.a
aMolecular Genetics Unit, bLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Md., USA; cReta Lila Weston Institute of Neurological Studies, University College London, London, UK; dDepartment of Neurology, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taipei, Taiwan; eNeurogenetics Unit, Department of Neurology, Medical School, University of Thessaly, Larissa, Greece; fDepartment of Neurology, Seinäjoki Central Hospital, Seinäjoki, and gDepartment of Neurology, Helsinki University Central Hospital and University of Helsinki, Biomedicum-Helsinki, Neuroscience Programme, Helsinki, Finland

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 5/18/2006
Accepted: 7/3/2006
Published online: 1/11/2007
Issue release date: January 2007

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 4

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: http://www.karger.com/NDD

Abstract

Background: The overlap in the clinical and pathological features of tauopathies and synucleinopathies raises the possibility that the tau protein may be important in Parkinson’s disease (PD) pathogenesis. Several MAPT polymorphisms that define the tau H1 haplotype have been investigated for an association with PD with conflicting results; however, two meta-analyses support an association between haplotype H1 and PD. Methods: In this study, we recruited 508 patients and 611 healthy controls from Greek, Finnish and Taiwanese populations. We examined the possible genetic role of variation within MAPT in PD using haplotype-tagging single polymorphisms (SNPs) in these ethnically different PD populations. Results: We identified a moderate association at SNP rs3785883 in the Greek cohort for both allele and genotype frequency (p = 0.01, p = 0.05, respectively) as well as for SNP rs7521 (genotype p = 0.02) and rs242557 (p = 0.01 genotypic, p = 0.04 allelic) in the Finnish population. There were no significant differences in genotype or allele distribution between cases and controls in the Taiwanese cohort. Conclusion: We failed to demonstrate a consistent association between the MAPT H1 haplotype (delineated by intron 9 ins/del) and PD in three ethnically diverse populations. However, the data presented here suggest that subhaplotypes of haplotype H1 may confer susceptibility to PD, and that either allelic heterogeneity or different haplotype composition explain the divergent haplotype results.

© 2006 S. Karger AG, Basel


  

Author Contacts

Dr. Andrew Singleton
Laboratory of Neurogenetics, National Institute on Aging
Porter Neuroscience Building, 35, Convent Drive
Bethesda, MD 20892 (USA)
Tel. +1 301 451 3825, Fax +1 301 451 7295, E-Mail Singleta@mail.nih.gov

  

Article Information

Received: May 18, 2006
Accepted: July 3, 2006
Number of Print Pages : 7
Number of Figures : 0, Number of Tables : 4, Number of References : 24

  

Publication Details

Neurodegenerative Diseases

Vol. 3, No. 6, Year 2006 (Cover Date: January 2007)

Journal Editor: Nitsch, R.M. (Zürich)
ISSN: 1660–2854 (print), 1660–2862 (Online)

For additional information: http://www.karger.com/NDD


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 5/18/2006
Accepted: 7/3/2006
Published online: 1/11/2007
Issue release date: January 2007

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 4

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: http://www.karger.com/NDD


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.